

10/043912**WEST**[Help](#)[Logout](#)[Interrupt](#)Search results
for Paper # 7[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#) | [Cases](#)**Search Results -****Terms****Documents**

L12 and (MLV or GALV or MoMLV or HFV)

1

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Database:

Search: L14

Search History**DATE:** Tuesday, August 26, 2003 [Printable Copy](#) [Create Case](#)**Set Name Query**

side by side

Hit Count Set Name
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR*

<u>L14</u>	L12 and (MLV or GALV or MoMLV or HFV)	1	<u>L14</u>
<u>L13</u>	L12 and oncoretrovir\$	0	<u>L13</u>
<u>L12</u>	5830458 [pn]	2	<u>L12</u>
<u>L11</u>	tissue near specific near3 promoter\$ near10 LTR	74	<u>L11</u>
<u>L10</u>	L9 and (suicide or probasin or thymidine near kinase)	77	<u>L10</u>
<u>L9</u>	L8 and pharmaceuti\$	80	<u>L9</u>
<u>L8</u>	L6 and tissue near specific near3 promoter\$	107	<u>L8</u>
<u>L7</u>	L6 tissue near specific near3 promoter\$	5875	<u>L7</u>
<u>L6</u>	L3 and (oncoretrovir\$ or MLV or MoMLV or GALV or HFV) near10 LTR	240	<u>L6</u>
<u>L5</u>	L3 and oncoretrovir\$ near10 LTR	1	<u>L5</u>
<u>L4</u>	L3 and oncoretrovir\$	33	<u>L4</u>
<u>L3</u>	L2 and gag and pol and env	1442	<u>L3</u>
<u>L2</u>	retrovir\$ near5 vector\$	14890	<u>L2</u>
<u>L1</u>	6410313 [pn]	2	<u>L1</u>

END OF SEARCH HISTORY

Search Results - Record(s) 1 through 80 of 80 returned.

-
1. 20030157485 . 13 Nov 01. 21 Aug 03. Human cDNAs and proteins and uses thereof. Bejanin, Stephane, et al. 435/6; 435/226 435/320.1 435/325 435/69.1 435/7.2 530/388.26 536/23.2 800/8 C12Q001/68 G01N033/53 G01N033/567 A01K067/00 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
-
2. 20030157070 . 22 Oct 01. 21 Aug 03. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations. Jolly, Douglas J.. 424/93.21; 435/372 435/455 435/456 A61K048/00 C12N015/867 C12N005/08.
-
3. 20030144205 . 20 Dec 02. 31 Jul 03. Novel germ cell-specific contraceptive target. Matzuk, Martin M., et al. 514/12; 435/226 435/320.1 435/325 435/69.1 530/388.26 536/23.2 A61K038/16 C07H021/04 C12N009/64 C12P021/02 C12N005/06 C07K016/40.
-
4. 20030144204 . 19 Dec 02. 31 Jul 03. Akt-based inducible survival switch. Spencer, David. 514/12; 435/320.1 435/325 514/44 530/350 536/23.5 A61K048/00 C07K014/705 A61K038/17 C07H021/04.
-
5. 20030143702 . 31 Oct 02. 31 Jul 03. Vesicular monoamine transporter gene therapy in parkinson's disease. Kang, Un Jung. 435/128; 435/325 435/455 435/456 C12P013/00 C12N015/861 C12N015/867 C12N005/06.
-
6. 20030143228 . 29 Oct 02. 31 Jul 03. Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen. Chen, Si-Yi, et al. 424/144.1; 435/320.1 435/334 435/69.1 530/388.22 536/23.53 A61K039/395 C07H021/04 C07K016/28 C12P021/02 C12N005/06 C07K014/74.
-
7. 20030139324 . 19 Nov 02. 24 Jul 03. Tumor suppressor designated TS10q23.3. Steck, Peter, et al. 514/2; 435/184 435/320.1 435/325 435/6 435/7.23 536/23.2 A61K038/17 C12Q001/68 G01N033/574 C12N009/99 C07H021/04 C12P021/02 C12N005/06.
-
8. 20030138412 . 27 Jun 02. 24 Jul 03. Inhibition of tumor growth and metastasis by N5 gene. Goodrich, David W., et al. 424/93.21; 435/7.23 514/44 A61K048/00 G01N033/574.
-
9. 20030113920 . 20 Dec 02. 19 Jun 03. Lentiviral LTR-deleted vector. Kingsman, Alan John, et al. 435/456; 435/235.1 435/320.1 435/325 435/69.1 C12N015/867 C12P021/02 C12N005/06 C12N007/00.
-
10. 20030113898 . 30 Apr 02. 19 Jun 03. Methods for producing high titre vectors and compositions used in such methods. Olsen, John C., et al. 435/235.1; 435/366 435/455 435/456 C12N007/00 C12N005/08 C12N015/86 C12N007/01 C12N015/63 C12N015/85 C12N015/87 C12N015/86.
-
11. 20030104611 . 01 Jun 01. 05 Jun 03. Feline immunodeficiency virus gene therapy vectors. Johnston, Julie C., et al. 435/320.1; 424/199.1 435/235.1 435/325 A61K039/12 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02.
-
12. 20030096397 . 18 Feb 00. 22 May 03. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Schlesinger, Sondra, et al. 435/320.1; 435/69.1 435/91.1

435/91.2 C12P021/06 C12P019/34 A61K031/665 A01N057/00 C12N015/00 C12N015/09 C12N015/63
C12N015/70 C12N015/74.

13. 20030096247 . 14 Nov 01. 22 May 03. Human cDNAs and proteins and uses thereof.
Bejanin, Stephane, et al. 435/6; 435/183 435/320.1 435/325 435/69.1 530/350 536/23.2 800/8
C12Q001/68 A01K067/00 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
14. 20030092882 . 29 Jun 01. 15 May 03. Host cells containing multiple integrating vectors.
Bremel, Robert D., et al. 530/350; 435/320.1 435/325 435/69.1 C07K014/435 C12P021/02 C12N005/06
C12N015/00.
15. 20030092660 . 01 Jul 02. 15 May 03. Compositions and methods for treating
papillomavirus-infected cells. Howley, Peter M., et al. 514/44; 424/204.1 435/325 514/12 536/23.1
A61K038/00 C07H021/02 C07H021/04 A61K031/70 A01N043/04 A61K039/12 C12N005/00
C12N005/02.
16. 20030092011 . 14 Nov 01. 15 May 03. Human cDNAs and proteins and uses thereof.
Bejanin, Stephane, et al. 435/6; 435/183 435/320.1 435/325 435/69.1 435/7.9 536/23.2 800/3
C12Q001/68 G01N033/53 G01N033/542 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
17. 20030083290 . 29 Jan 02. 01 May 03. Vector system. Kingsman, Alan J., et al. 514/44;
424/155.1 435/320.1 A61K048/00 A61K039/395.
18. 20030083261 . 30 Apr 01. 01 May 03. Class of 12mer peptides that inhibit the function of the
mitotic check point protein Mad2. Yu, Hongtao, et al. 514/13; 514/14 514/15 514/16 A61K038/10
A61K038/08.
19. 20030082722 . 05 Aug 02. 01 May 03. Method for amplifying expression from a cell specific
promoter. Fang, Bingliang. 435/69.1; 435/320.1 435/325 435/455 C12P021/02 C12N005/06
C12N015/00.
20. 20030072758 . 21 May 02. 17 Apr 03. BMPR1A involvement in juvenile polyposis. Howe,
James R.. 424/155.1; 435/6 435/7.23 C12Q001/68 G01N033/574 A61K039/395.
21. 20030051259 . 08 Jul 02. 13 Mar 03. Packaging cells. Barber, Jack R., et al. 800/4; 435/235.1
435/366 C12N005/08 C12P021/00 C12N007/00.
22. 20030049251 . 08 Aug 01. 13 Mar 03. Methods and compositions useful for inhibiting
CCR5-dependent infection of cells by HIV-1. Barbas, Carlos F., et al. 424/144.1; 424/142.1 530/388.1
A61K039/395 C07K016/28.
23. 20030027248 . 06 Aug 01. 06 Feb 03. Human cDNAs and proteins and uses thereof. Bejanin,
Stephane, et al. 435/69.1; 435/183 435/320.1 435/325 435/6 530/350 536/23.2 C12P021/02
C12Q001/68 C07H021/04 C12N009/00 C12N005/06.
24. 20030027161 . 13 Nov 01. 06 Feb 03. Human cDNAs and proteins and uses thereof. Bejanin,
Stephane, et al. 435/6; 435/183 435/320.1 435/325 435/69.1 530/350 536/23.2 800/8 C12Q001/68
A01K067/00 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
25. 20030003567 . 24 Jul 02. 02 Jan 03. Packaging cells. Barber, Jack R., et al. 435/235.1;
435/366 435/5 C12Q001/70 C12N007/00 C12N005/08.
26. 20030003565 . 27 Nov 01. 02 Jan 03. Functional lentiviral vector from an MLV-based

backbone. Dubensky, Thomas W. JR., et al. 435/235.1; 424/188.1 435/320.1 435/456 A61K039/21 C12N007/00 C12N015/867.

27. 20020182723 . 12 Jun 01. 05 Dec 02. AN IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS. Zhang, Shuyuan, et al. 435/320.1; 424/233.1 435/235.1 435/239 536/23.72 536/24.1 C12N007/01 C12N015/861 C07H021/04 A61K039/235.

28. 20020150931 . 18 Dec 01. 17 Oct 02. Bardet-biedl susceptibility gene and uses thereof. Sheffield, Val, et al. 435/6; 435/183 435/320.1 435/325 435/69.1 435/7.92 536/23.2 C12Q001/68 G01N033/53 G01N033/537 G01N033/543 C07H021/04 C12N009/00 C12P021/02 C12N005/06.

29. 20020127697 . 11 Jan 02. 12 Sep 02. Gene delivery system and methods of use. Kasahara, Noriyuki, et al. 435/235.1; 435/456 C12N007/00 C12N015/867.

30. 20020123479 . 12 Oct 01. 05 Sep 02. Immunostimulation mediated by gene-modified dendritic cells. Song, Elizabeth S., et al. 514/44; 424/144.1 424/93.21 435/235.1 435/456 A61K048/00 A61K039/395 C12N007/01 C12N015/867.

31. 20020100069 . 09 Jan 02. 25 Jul 02. Methods for preventing cardiac hypertrophy and heart failure by inhibition of MEF2 transcription factor inhibitor. Olson, Eric N.. 800/8; 424/146.1 514/44 A01K067/00 A61K039/395 A61K048/00.

32. 20020082224 . 13 Jan 98. 27 Jun 02. NON-IMMUNOGENIC PRODRUGS AND SELECTABLE MARKERS FOR USE IN GENE THERAPY. JOLLY, DOUGLAS J., et al. 514/44; 424/93.1 435/320.1 A61K048/00.

33. 20020068354 . 01 Mar 01. 06 Jun 02. Feline immunodeficiency virus gene therapy vectors. Johnston, Julie C., et al. 435/235.1; 435/320.1 435/456 530/826 536/23.72 536/24.1 C12N007/01 C12N015/867 C07H021/04 C07K001/00 C12N015/74 C12N015/63.

34. 20020061862 . 13 Nov 01. 23 May 02. Inducible nitric oxide synthase for treatment of disease. Billiar, Timothy R., et al. 514/44; 424/450 435/320.1 435/456 A61K048/00 A61K009/127 C12N015/861.

35. 20020061297 . 27 Sep 01. 23 May 02. Novel recombinant DNA vectors for gene therapy. Gunzburg, Walter H., et al. 424/93.21; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N007/01 C12N015/86 C12N015/861 C12N015/867.

36. 20020048805 . 15 Jan 99. 25 Apr 02. FELINE IMMUNODEFICIENCY VIRUS GENE THERAPY VECTORS. JOHNSTON, JULIE C., et al. 435/235.1; C12P013/14 C12N007/00 C12N007/01.

37. 20020018995 . 29 Nov 00. 14 Feb 02. Methods and compositions for diagnosing tauopathies. Ghetti, Bernardino, et al. 435/6; 435/7.21 435/7.92 C12Q001/68 G01N033/567 G01N033/53 G01N033/537 G01N033/543.

38. 20010036929 . 26 Apr 01. 01 Nov 01. Xrcc3 is required for assembly of Rad51-complexes in vivo. Weichselbaum, Ralph R., et al. 514/44; 424/649 514/34 A61K048/00 A61K033/24.

39. 20010011078 . 22 Dec 00. 02 Aug 01. DNA fragmentation factor involved in apoptosis. Wang, Xiaodong, et al. 514/44; 424/93.2 424/94.6 435/196 435/320.1 435/6 530/388.26 536/23.2 A61K048/00 C07H021/04 C07K016/40 A61K038/46 C12N009/16 A61K031/713.

40. 6592874 . 18 Feb 00; 15 Jul 03. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Schlesinger; Sondra, et al. 424/218.1; 424/219.1 435/235.1 435/236. A61K039/193.
41. 6540995 . 18 Nov 99; 01 Apr 03. Encapsulated cells producing cytochrome P450. Gunzburg; Walter H., et al. 424/93.21; 424/93.1 424/93.2 435/320.1 435/325 435/455 514/44. A01N063/00 A01N043/04 C12N005/00 C12N015/00 C12N015/63.
42. 6517828 . 26 May 00; 11 Feb 03. C-CAM as an angiogenesis inhibitor. Lin; Sue-Hwa, et al. 424/93.2; 435/320.1 514/44 530/350 536/23.5. C12N015/79 A61K048/00.
43. 6506378 . 15 Dec 99; 14 Jan 03. Vesicular monoamine transporter gene therapy in Parkinson's disease. Kang; Un Jung. 424/93.21; 424/93.1 424/93.2 435/320.1 435/325 435/375 435/69.1 514/44 536/23.1 536/23.5. A01N063/00 A01N043/04 A61K048/00 C12N015/00 C12N005/00 C07H021/02 C07H021/04.
44. 6495349 . 05 Jun 95; 17 Dec 02. Chimeric gene constructs. Gruber; Harry E., et al. 435/91.1; 435/320.1 435/325 435/366 435/455 435/456 435/91.4 435/91.51 536/23.1 536/23.2 536/23.5 536/23.72 536/24.1. C12N015/867 C12N015/63 C12N005/10.
45. 6485965 . 08 Jun 00; 26 Nov 02. Replicating or semi-replicating viral constructs, preparation and uses for gene delivery. Klatzmann; David, et al. 435/320.1; 435/69.1 536/23.72. C12N015/00 C12P021/06 C07H021/04.
46. 6482795 . 26 Aug 98; 19 Nov 02. Tumor suppressor designated TS10q23.3. Steck; Peter, et al. 514/2; 514/12 514/21 530/350. A61K038/00 A61K038/16 A61K038/17 C07K014/00 C07K014/435.
47. 6465634 . 08 Oct 99; 15 Oct 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 536/23.72; 435/320.1. C07H021/04.
48. 6458560 . 08 Oct 99; 01 Oct 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/457. C12P021/06.
49. 6451592 . 06 Oct 97; 17 Sep 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 435/320.1; 435/69.1 435/69.3 435/69.51 435/69.52. C12N015/00 C12N015/19 C12N015/24.
50. 6432926 . 27 Jul 99; 13 Aug 02. Compositions and methods for treating papillomavirus-infected cells. Howley; Peter M., et al. 514/44; 424/204.1 435/325 435/455 514/12 536/23.1. A61K048/00 A61K039/12 C12N015/63.
51. 6426196 . 08 Oct 99; 30 Jul 02. Alphavirus structural protein expression cassettes. Dubensky, Jr.; Thomas W., et al. 435/69.1; 536/23.72. C12P021/06 C07H021/04.
52. 6423491 . 13 May 99; 23 Jul 02. Method of diagnosing juvenile polyposis (JP). Howe; James R., et al. 435/6; 435/4 435/7.1 435/7.21 435/7.23 435/7.92 435/7.95 436/63 436/64. C12Q001/00 C12Q001/68 G01N033/567 G01N033/574 G01N033/53.
53. 6420335 . 16 Jun 99; 16 Jul 02. Combination of radiotherapy and anti-angiogenic factors. Weichselbaum; Ralph R., et al. 514/2; 378/65 514/1 530/350 600/1. A01N037/18 A01N005/10 A01N061/00 A01N005/00 C07K001/00.

54. 6410326 . 07 Jun 95; 25 Jun 02. Method for inhibiting human tumor cells. Gruber; Harry E., et al. 435/455;. C12N015/63.
55. 6410313 . 01 Oct 99; 25 Jun 02. Gene delivery system and methods of use. Kasahara; Noriyuki, et al. 435/320.1; 424/93.2 435/235.1 435/455 435/456 514/44 530/350 536/23.1. C07H021/02 A61K048/00 C12N007/01 C12N015/63 C12N015/867.
56. 6395959 . 06 May 96; 28 May 02. Nucleotide sequence encoding the enzyme I SceI and the use thereof. Dujon; Bernard, et al. 800/18; 435/320.1 435/325 435/455 800/25. A01K067/027 C12N015/00 C12N015/63 C12N015/85.
57. 6391632 . 08 Oct 99; 21 May 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 435/325; 435/457 435/69.1 536/23.72. C12N005/10.
58. 6372957 . 10 Nov 99; 16 Apr 02. Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use. Olson; Eric N.. 800/18; 800/13 800/3 800/9. A01K067/027 A01K067/00 A01K067/033 G01N033/00.
59. 6241982 . 06 Jun 95; 05 Jun 01. Method for treating brain cancer with a conditionally lethal gene. Barber; Jack R., et al. 424/93.2;. A61K048/00.
60. 6165737 . 16 Apr 98; 26 Dec 00. DNA fragmentation factor involved in apoptosis. Wang; Xiaodong, et al. 435/7.6; 435/23 435/252.3 435/252.33 435/320.1 435/7.91 536/23.2. C12Q001/00 C12Q001/37 C12N009/64 C12N015/70 C12N015/74.
61. 6133029 . 06 Jun 95; 17 Oct 00. Replication defective viral vectors for infecting human cells. Gruber; Harry E., et al. 435/366; 435/325. C12N005/10.
62. 5997859 . 06 Jun 95; 07 Dec 99. Method for treating a metastatic carcinoma using a conditionally lethal gene. Barber; Jack R., et al. 424/93.2; 514/44. A61K048/00 A61K031/70.
63. 5889156 . 24 May 95; 30 Mar 99. TNF deletion muteins. Kriegler; Michael, et al. 530/351; 424/85.1 530/395 930/144. C07K014/525.
64. 5888814 . 24 May 95; 30 Mar 99. Recombinant host cells encoding TNF proteins. Kriegler; Michael, et al. 435/360; 424/93.1 424/93.21 424/93.7 435/252.3 435/320.1 435/325 435/363 435/366 435/371 435/372 435/372.1 435/69.5 536/23.5. C12N015/74 C12N005/08.
65. 5888502 . 05 Jun 95; 30 Mar 99. Recombinant retroviruses. Guber; Harry E., et al. 424/93.21; 424/93.2 435/320.1 435/372.3. A61K048/00 C12N005/10 C12N015/86.
66. 5874077 . 24 May 95; 23 Feb 99. Human til cells expressing recombinant TNF prohormone. Kriegler; Michael, et al. 424/93.21; 435/372.3 435/69.7. A61K045/05 C12N005/22.
67. 5863797 . 24 May 95; 26 Jan 99. Gene fusion encoding a hypersecretor protein. Kriegler; Michael, et al. 435/366; 435/320.1 435/325 435/367 435/368 435/369 435/370 435/371 435/372 435/372.2 435/372.3 536/23.4 536/23.5. C12N005/10.
68. 5861290 . 22 Oct 92; 19 Jan 99. Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders. Goldsmith; Mark A., et al. 435/456; 424/93.2 435/320.1 514/44 536/23.1 536/23.2 536/23.5 536/23.53 536/23.6 536/23.7 536/23.72 536/24.1 536/24.5. C12N015/09 C12N015/11 C12N015/63 C12N015/86.

69. 5856185 . 07 Jun 95; 05 Jan 99. Method for making reflection defective retroviral vectors for infecting human cells. Gruber; Harry E., et al. 435/372; 435/350 435/357 435/363 435/366 435/369 536/23.4 536/23.72. C07H021/04 C12N005/10 C12N015/48.
70. 5851529 . 07 Jun 95; 22 Dec 98. Recombinant retroviruses. Guber; Harry E., et al. 424/188.1; 424/277.1 424/93.2. A61K039/21 A61K039/00 A61K048/00.
71. 5849586 . 05 Jun 95; 15 Dec 98. Infective protein delivery system. Kriegler; Michael, et al. 435/372; 424/93.2 424/93.21 435/235.1 435/320.1 435/325 435/363 435/366 435/372.2 435/372.3 536/23.1 536/23.5 536/23.52. C12N005/08 C12N015/19 C12N015/23.
72. 5830458 . 07 Jun 95; 03 Nov 98. Method for destroying a diseased human cell. Gruber; Harry E., et al. 424/93.2; 424/93.21 424/93.6. A61K048/00.
73. 5817491 . 22 Dec 94; 06 Oct 98. VSV G pseudotyped retroviral vectors. Yee; Jiing-Kuan, et al. 435/456; 424/93.2 435/320.1 435/325 435/366 435/465. C12N015/86 C12N005/10 C12N005/08.
74. 5716832 . 05 Jun 95; 10 Feb 98. Packaging cells. Barber; Jack R., et al. 435/235.1; 435/325. C12N015/00 C12N005/10.
75. 5716826 . 12 Oct 93; 10 Feb 98. Recombinant retroviruses. Gruber; Harry E., et al. 435/320.1; 536/23.5 536/23.72. G12N015/86 G07H021/04.
76. 5716613 . 07 Jun 95; 10 Feb 98. Recombinant retroviruses. Guber; Harry E., et al. 424/93.2; 435/320.1. A61K048/00 C12N015/86.
77. 5691177 . 05 Jun 95; 25 Nov 97. Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent. Guber; Harry E., et al. 435/456; 435/372 435/69.1. C12N005/08 C12N005/10.
78. 5681746 . 30 Dec 94; 28 Oct 97. Retroviral delivery of full length factor VIII. Bodner; Mordechai, et al. 435/350; 435/320.1 435/366 435/371 536/23.5. C12N005/00 C12N015/63 C07H021/04.
79. 5658565 . 24 Jun 94; 19 Aug 97. Inducible nitric oxide synthase gene for treatment of disease. Billiar; Timothy R., et al. 424/93.21; 424/93.1 424/93.2 435/189 435/191 435/235.1 435/320.1 514/44 536/23.1 536/23.2 536/23.5. A61K048/00.
80. 5591624 . 23 Nov 93; 07 Jan 97. Retroviral packaging cell lines. Barber; Jack R., et al. 435/366; 435/320.1 435/369. C12N005/10 C12N005/08.

Terms	Documents
L8 and pharmaceuti\$	80

[Previous Page](#) [Next Page](#)